Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/10/2017 01/11/2017 01/12/2017 01/13/2017 01/17/2017 Date
0.6387(c) 0.6421(c) 0.6408(c) 0.6299(c) 0.6101(c) Last
250 484 555 062 325 364 1 023 129 654 486 Volume
+1.22% +0.53% -0.20% -1.70% -3.14% Change
More quotes
Financials ($)
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
01/06 NAVIDEA BIOPHARMACEUTICALS : to Present at Upcoming Investor Conference
2016 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
2016 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Entry into a Material ..
2016 NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, F..
2016 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
2016 Navidea Reports 2016 Third Quarter Financial Results
2016 NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
2016 NAVIDEA BIOPHARMACEUTICALS : to Announce Third Quarter 2016 Financial Results on..
2016 NAVIDEA BIOPHARMACEUTICALS (NYSEMKT : NAVB) Files An 8-K Reports 2016 Third Quar..
2016 NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%
2016 Trading in Navidea halted pending news
2016 Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q3 2016 Results - ..
2016 Navidea Biopharm net loss improves in Q3
2016 Navidea Biopharm beats by $0.02, beats on revenue
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-1.19%98
INCYTE CORPORATION17.43%22 182
QUINTILES IMS HOLDINGS..1.46%18 995
CELLTRION, INC.--.--%10 650
LONZA GROUP AG5.05%9 643
ALKERMES PLC-0.22%8 428
More Results